Examine the genetic profile of women with ovarian cancer in order to identify druggable targets

​Annually more than 500 Danish women are diagnosed with ovarian cancer. The treatment is often surgery and chemotherapy. Unfortunately, approximately 20% of patients are resistant to treatment - and 80% with primary response will relapse. We will examine the genetic profile of women with ovarian cancer in order to identify druggable targets. 

A research project by PhD-student Yagmur Sisman

Annually more than 500 Danish women are diagnosed with ovarian cancer, which is the deadliest form of gynecological cancer in the western world. The treatment is often surgery followed by chemotherapy and possibly biological drugs. Unfortunately, approximately 20% of patients are resistant to treatment - and 80% with primary response will relapse.

We will examine the genetic profile of women with ovarian cancer in order to identify genetic changes in chemoresistant and recurrent patients. The purpose is to identify genetic markers with the possibility of treatment with drugs that are currently used for other cancers. 

In addition, we will investigate the genetic differences in cancer tissue from solid tumor, metastases and peritoneal fluid in order to obtain comprehensive genetic information about the individual patient's cancer, and thus the best conditions to predict whether a patient will benefit from a given treatment.



Responsible editor